Skip to main content
. Author manuscript; available in PMC: 2013 Nov 24.
Published in final edited form as: Biol Blood Marrow Transplant. 2010 Feb 1;16(5):10.1016/j.bbmt.2009.12.007. doi: 10.1016/j.bbmt.2009.12.007

Figure 3.

Figure 3

Splenectomized, aly/aly (LN/PP/Sp−/−) mice develop significant clinical and target organ GVHD following allo-BMT from MHC mismatched B10.BR donors. Lethally irradiated, splenectomized aly/aly mice (LN/PP/Sp−/−) received BMT from syngeneic aly/aly or allogeneic B10.BR donors as described in the Materials and Methods section. Littermate, sham splenectomized aly/+ mice (LN/PP/Sp+/+) served as allo-BMT controls. Wildt-ype C57BL/6 recipients of C57BL/6 of B10.BR BMT served as additional positive GVHD controls. The severity of GVHD was subsequently assessed by survival (A) and clinical score (B). ◆ syngeneic, ■ C57BL/6, ▲ LN/PP/Sp+/+ ● LN/PP/Sp−/−. Target organ histopathology in the liver (C) and intestinal tract (D) was also examined in surviving LN/PP/SP−/− allogeneic mice at 6 to 7 weeks after BMT. Data are expressed as mean ± SEM from of 3 (survival and clinical score) or 2 (target organ pathology) different experiments. n=12 to 18 (survival and clinical score) or 8 to 12 (pathology) per group; *p<0.01 compared to syngeneic controls. syn Inline graphic LN/PP/Sp−/− ■.